HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Immunology · Autoimmune Diseases Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Immunology · Autoimmune Diseases Competitive Landscape

22 findings · 95 signals · 7 insights

Type

Competitive Landscape Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 80%

Evidence

117 items

Sources

5

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Immunology · Autoimmune Diseases synthesizes 22 Competitiva findings across 95 active signals. 7 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Roche — ILUMYA

    Roche is a direct competitive threat because it is already approved in Immunology · IL-23 (ILUMYA) and could narrow Merck's development lead.

    View detail
  2. competitive

    Roche — XELJANZ

    Roche is a direct competitive threat because it is already approved in Immunology · JAK Inhibitor (XELJANZ) and could narrow Pfizer's development lead.

    View detail
  3. competitive

    Roche — XELJANZ XR

    Roche is a direct competitive threat because it is already approved in Immunology · JAK Inhibitor (XELJANZ XR) and could narrow Pfizer's development lead.

    View detail
  4. competitive

    Roche — Anifrolumab

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  5. competitive

    Roche — Anifrolumab

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  6. competitive

    Bristol Myers Squibb — Anifrolumab

    Bristol Myers Squibb is a direct competitive threat because it has a development-stage program in Immunology · Systemic Lupus Erythematosus (Anifrolumab) and could narrow AstraZeneca's development lead.

    View detail
  7. competitive

    Roche — Anifrolumab

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  8. competitive

    Roche — Anifrolumab

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  9. competitive

    Pfizer — OLUMIANT

    Pfizer is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    View detail
  10. competitive

    Pfizer — OLUMIANT

    Pfizer is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    View detail
  11. competitive

    Roche — OLUMIANT

    Roche is a direct competitive threat because it is already approved in Immunology · JAK Inhibitor (OLUMIANT) and could narrow Lilly's development lead.

    View detail
  12. competitive

    AstraZeneca — OLUMIANT

    AstraZeneca is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 7 high-pressure competitive programs for portfolio displacement risk. Cross-reference 7 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Roche — ILUMYA

    75%

    Roche is a direct competitive threat because it is already approved in Immunology · IL-23 (ILUMYA) and could narrow Merck's development lead.

    Source: Humanexa Signals

    View evidence

  • Roche — XELJANZ

    61%

    Roche is a direct competitive threat because it is already approved in Immunology · JAK Inhibitor (XELJANZ) and could narrow Pfizer's development lead.

    Source: Humanexa Signals

    View evidence

  • Roche — XELJANZ XR

    62%

    Roche is a direct competitive threat because it is already approved in Immunology · JAK Inhibitor (XELJANZ XR) and could narrow Pfizer's development lead.

    Source: Humanexa Signals

    View evidence

  • Roche — Anifrolumab

    79%

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — Anifrolumab

    79%

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Bristol Myers Squibb — Anifrolumab

    86%

    Bristol Myers Squibb is a direct competitive threat because it has a development-stage program in Immunology · Systemic Lupus Erythematosus (Anifrolumab) and could narrow AstraZeneca's development lead.

    Source: Bristol Myers Squibb

    View evidence

  • Roche — Anifrolumab

    95%

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — Anifrolumab

    65%

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Humanexa Signals

    View evidence

  • Pfizer — OLUMIANT

    82%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    Source: Pfizer

    View evidence

  • Pfizer — OLUMIANT

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    Source: Humanexa Signals

    View evidence

  • Roche — OLUMIANT

    86%

    Roche is a direct competitive threat because it is already approved in Immunology · JAK Inhibitor (OLUMIANT) and could narrow Lilly's development lead.

    Source: Humanexa Signals

    View evidence

  • AstraZeneca — OLUMIANT

    86%

    AstraZeneca is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    Source: Humanexa Signals

    View evidence

  • Roche — Anifrolumab

    95%

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Roche

    View evidence

  • Roche — Anifrolumab

    95%

    Roche is a regulatory competitive threat because recent agency-facing activity on Anifrolumab in Immunology · Systemic Lupus Erythematosus may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Humanexa Signals

    View evidence

  • Roche — Pipeline activity

    85%

    Roche poses commercial pressure in Immunology · Lupus and Rheumatoid Arthritis: Pipeline activity language points to share, pricing, or access competition that could erode Merck's launch economics even before clinical differentiation is proven.

    Source: Roche

    View evidence

  • Roche — Pipeline activity

    85%

    Roche poses commercial pressure in Immunology · Lupus and Rheumatoid Arthritis: Pipeline activity language points to share, pricing, or access competition that could erode Merck's launch economics even before clinical differentiation is proven.

    Source: Roche

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

    Regulatory Approval

  • FDA Approves ANDA for Tofacitinib Citrate by Sun Pharma

    Regulatory Approval

  • FDA Grants Approval for Tofacitinib Citrate (ANDA217298)

    Regulatory Approval

  • FDA Grants Approval for Tofacitinib Citrate ANDA220137

    Regulatory Approval

  • FDA Approves Supplement for ULTOMIRIS (Ravulizumab-Cwvz)

    Regulatory Approval

  • FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma

    Regulatory Approval

  • FDA Grants Priority Review for VYVGART HYTRULO Supplement by ARGENX

    Regulatory Approval

  • FDA Grants Priority Review for VYVGART Supplement Application

    Regulatory Approval

Insights

  • Competitive Dynamics in Hereditary Angioedema Trials: Astria vs.

    Immunology · Hereditary Angioedema

  • Enhancing Vaccine Efficacy in the Elderly Through Immunostimulatory Adjuvants

    Immunology · Vaccine Development

  • Optimizing mAb Formulations Through Excipient Interactions for Competitive Advantage

    Immunology · Monoclonal Antibodies

  • Emerging Generic Competition for Tofacitinib: Strategic Implications for Market Players

    Immunology · JAK Inhibitor

  • Emerging Competitive Dynamics in Rare Disease Immunology: Plerixafor and Genetic Insights

    Immunology · Rare Disease

  • Increased Competitive Pressure in JAK Inhibitor and Corticosteroid Markets

    Immunology · JAK Inhibitor

  • Regulatory Advances in Immunology: Implications for Competitive Dynamics

    Immunology · Systemic Lupus Erythematosus

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Merck

    132 signals

  • AstraZeneca

    127 signals

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Janssen

    36 signals

  • AbbVie

    26 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.